Clinical Report: Reestablishing Immune Balance in the Spinal Microenvironment

Overview

This review discusses chronic inflammatory diseases of the spine, particularly axial spondyloarthritis (axSpA) and intervertebral disc degeneration (IDD), highlighting the limitations of current therapies.

Background

Chronic inflammatory spinal disorders, such as axSpA and IDD, significantly impact patient quality of life and functional ability. The unique spinal microenvironment, characterized by mechanical loading and hypoxia, contributes to the pathogenesis of these conditions.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Chronic inflammatory diseases of the spine impose a substantial burden through pain and structural changes.
• Current therapies primarily target inflammatory cytokines but do not effectively halt structural deterioration.
• The spinal microenvironment influences immune cell behavior and contributes to chronic inflammation.
• Shared mechanisms between axSpA and IDD include mechanical loading and activation of inflammatory pathways.

Clinical Implications

Clinicians should consider the unique characteristics of the spinal microenvironment when treating axSpA and IDD.

Conclusion

A comprehensive understanding of the spinal microenvironment may lead to new insights into chronic spinal inflammatory diseases.

Related Resources & Content

1. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
2. UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis
3. Intervertebral disc degeneration | Nature Reviews Disease Primers
4. Frontiers in Immunology — Mechanical cues as immunomodulators in neuroinflammation-driven spinal sensitization: analgesic mechanisms and therapeutic strategies
5. Frontiers in Immunology — Editorial: Host-microbe immunometabolic chat: a new era of organismal communication
6. Frontiers in Immunology — The immune dysregulation landscape and dynamic regulation of competing endogenous RNAs in spinal cord injury
7. Frontiers in Neurology — The Role of Microglial Tim-3 in Neuroinflammation and Functional Recovery after Spinal Cord Injury
8. Mechanical cues as immunomodulators in neuroinflammation-driven spinal sensitization: analgesic mechanisms and therapeutic strategies
9. Editorial: Host-microbe immunometabolic chat: a new era of organismal communication
10. The immune dysregulation landscape and dynamic regulation of competing endogenous RNAs in spinal cord injury
11. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
12. UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis | UCB
13. Intervertebral disc degeneration | Nature Reviews Disease Primers